A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer

Paola Gazzaniga, Angela Gradilone, Ettore De Berardinis, Alessandro Sciarra, Cristiano Cristini, Giuseppe Naso, Franco Di Silverio, Luigi Frati, Anna Maria Aglianò

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVE To describe the design of a new chemosensitivity assay based on the expression of genes involved in the resistance to standard intravesical regimens, to allow individualization of therapy for high-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS To date, 35 patients with high-risk no-nmuscle-invasive bladder cancer have been enrolled, all candidates for transurethral resection of the bladder (TURB) followed by intravesical treatment. The intravesical regimen was chosen according to the risk profile of each patient. All patients were evaluated by cystoscopy 3 and 6 months after TURB. According to the molecular characterization of each tumour, our team of molecular oncologists determined for each patient a molecular profile of chemosensitivity to BCG, mitomycin c, anthracyclines and gemcitabine. This profile was then correlated to the response to intravesical therapy 6 months after TURB. RESULTS This chemosensitivity test was able to predict response to treatment in 96% of patients. The assay is easy to perform, inexpensive and quick. CONCLUSION Our results, although preliminary, are encouraging for the future of an individualized therapeutic approach, with the aim to provide a higher treatment success rate while sparing patients unnecessary toxicity from drugs that are not suited for their tumours.

Original languageEnglish
Pages (from-to)184-188
Number of pages5
JournalBJU International
Volume104
Issue number2
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
gemcitabine
Therapeutics
Cystoscopy
Anthracyclines
Mitomycin
Mycobacterium bovis
Drug-Related Side Effects and Adverse Reactions
Neoplasms
Gene Expression

Keywords

  • Chemosensitivity test
  • Drug resistance
  • Intravesical therapy
  • Non-muscle-invasive bladder cancer

ASJC Scopus subject areas

  • Urology

Cite this

Gazzaniga, P., Gradilone, A., De Berardinis, E., Sciarra, A., Cristini, C., Naso, G., ... Aglianò, A. M. (2009). A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer. BJU International, 104(2), 184-188. https://doi.org/10.1111/j.1464-410X.2008.08342.x

A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer. / Gazzaniga, Paola; Gradilone, Angela; De Berardinis, Ettore; Sciarra, Alessandro; Cristini, Cristiano; Naso, Giuseppe; Di Silverio, Franco; Frati, Luigi; Aglianò, Anna Maria.

In: BJU International, Vol. 104, No. 2, 07.2009, p. 184-188.

Research output: Contribution to journalArticle

Gazzaniga, P, Gradilone, A, De Berardinis, E, Sciarra, A, Cristini, C, Naso, G, Di Silverio, F, Frati, L & Aglianò, AM 2009, 'A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer', BJU International, vol. 104, no. 2, pp. 184-188. https://doi.org/10.1111/j.1464-410X.2008.08342.x
Gazzaniga, Paola ; Gradilone, Angela ; De Berardinis, Ettore ; Sciarra, Alessandro ; Cristini, Cristiano ; Naso, Giuseppe ; Di Silverio, Franco ; Frati, Luigi ; Aglianò, Anna Maria. / A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer. In: BJU International. 2009 ; Vol. 104, No. 2. pp. 184-188.
@article{2c05460a2fa743e69f0f94151b86383e,
title = "A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer",
abstract = "OBJECTIVE To describe the design of a new chemosensitivity assay based on the expression of genes involved in the resistance to standard intravesical regimens, to allow individualization of therapy for high-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS To date, 35 patients with high-risk no-nmuscle-invasive bladder cancer have been enrolled, all candidates for transurethral resection of the bladder (TURB) followed by intravesical treatment. The intravesical regimen was chosen according to the risk profile of each patient. All patients were evaluated by cystoscopy 3 and 6 months after TURB. According to the molecular characterization of each tumour, our team of molecular oncologists determined for each patient a molecular profile of chemosensitivity to BCG, mitomycin c, anthracyclines and gemcitabine. This profile was then correlated to the response to intravesical therapy 6 months after TURB. RESULTS This chemosensitivity test was able to predict response to treatment in 96{\%} of patients. The assay is easy to perform, inexpensive and quick. CONCLUSION Our results, although preliminary, are encouraging for the future of an individualized therapeutic approach, with the aim to provide a higher treatment success rate while sparing patients unnecessary toxicity from drugs that are not suited for their tumours.",
keywords = "Chemosensitivity test, Drug resistance, Intravesical therapy, Non-muscle-invasive bladder cancer",
author = "Paola Gazzaniga and Angela Gradilone and {De Berardinis}, Ettore and Alessandro Sciarra and Cristiano Cristini and Giuseppe Naso and {Di Silverio}, Franco and Luigi Frati and Aglian{\`o}, {Anna Maria}",
year = "2009",
month = "7",
doi = "10.1111/j.1464-410X.2008.08342.x",
language = "English",
volume = "104",
pages = "184--188",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer

AU - Gazzaniga, Paola

AU - Gradilone, Angela

AU - De Berardinis, Ettore

AU - Sciarra, Alessandro

AU - Cristini, Cristiano

AU - Naso, Giuseppe

AU - Di Silverio, Franco

AU - Frati, Luigi

AU - Aglianò, Anna Maria

PY - 2009/7

Y1 - 2009/7

N2 - OBJECTIVE To describe the design of a new chemosensitivity assay based on the expression of genes involved in the resistance to standard intravesical regimens, to allow individualization of therapy for high-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS To date, 35 patients with high-risk no-nmuscle-invasive bladder cancer have been enrolled, all candidates for transurethral resection of the bladder (TURB) followed by intravesical treatment. The intravesical regimen was chosen according to the risk profile of each patient. All patients were evaluated by cystoscopy 3 and 6 months after TURB. According to the molecular characterization of each tumour, our team of molecular oncologists determined for each patient a molecular profile of chemosensitivity to BCG, mitomycin c, anthracyclines and gemcitabine. This profile was then correlated to the response to intravesical therapy 6 months after TURB. RESULTS This chemosensitivity test was able to predict response to treatment in 96% of patients. The assay is easy to perform, inexpensive and quick. CONCLUSION Our results, although preliminary, are encouraging for the future of an individualized therapeutic approach, with the aim to provide a higher treatment success rate while sparing patients unnecessary toxicity from drugs that are not suited for their tumours.

AB - OBJECTIVE To describe the design of a new chemosensitivity assay based on the expression of genes involved in the resistance to standard intravesical regimens, to allow individualization of therapy for high-risk non-muscle-invasive bladder cancer. PATIENTS AND METHODS To date, 35 patients with high-risk no-nmuscle-invasive bladder cancer have been enrolled, all candidates for transurethral resection of the bladder (TURB) followed by intravesical treatment. The intravesical regimen was chosen according to the risk profile of each patient. All patients were evaluated by cystoscopy 3 and 6 months after TURB. According to the molecular characterization of each tumour, our team of molecular oncologists determined for each patient a molecular profile of chemosensitivity to BCG, mitomycin c, anthracyclines and gemcitabine. This profile was then correlated to the response to intravesical therapy 6 months after TURB. RESULTS This chemosensitivity test was able to predict response to treatment in 96% of patients. The assay is easy to perform, inexpensive and quick. CONCLUSION Our results, although preliminary, are encouraging for the future of an individualized therapeutic approach, with the aim to provide a higher treatment success rate while sparing patients unnecessary toxicity from drugs that are not suited for their tumours.

KW - Chemosensitivity test

KW - Drug resistance

KW - Intravesical therapy

KW - Non-muscle-invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=67650647141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650647141&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.08342.x

DO - 10.1111/j.1464-410X.2008.08342.x

M3 - Article

C2 - 19154503

AN - SCOPUS:67650647141

VL - 104

SP - 184

EP - 188

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -